SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'FloatPercentageOfTSO' CHRS (Coherus BioSciences) Float Percentage Of Total Shares
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » Float Percentage Of Total Shares Outstanding

Coherus BioSciences (Coherus BioSciences) Float Percentage Of Total Shares Outstanding

: 83.05% (As of Today)
View and export this data going back to 2014. Start your Free Trial

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Coherus BioSciences's float shares is 94.26 Mil. Coherus BioSciences's total shares outstanding is 113.50 Mil. Coherus BioSciences's float percentage of total shares outstanding is 83.05%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Coherus BioSciences's Insider Ownership is 1.29%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Coherus BioSciences's Institutional Ownership is 31.54%.

Coherus BioSciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Coherus BioSciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=94.26/113.50
=83.05%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus BioSciences (Coherus BioSciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
MGNX CRBU TERN MLYS ICVX SPRY ERAS URGN ITOS AGEN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
8C5:Germany
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Website
https://www.coherus.com
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Executives
Dennis M Lanfear director, officer: President and CEO C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell officer: Chief Financial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael officer: See Remarks C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider officer: Chief Commercial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton director 46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler officer: Chief Scientific Officer 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti officer: Chief, Quality & Compliance COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper director 150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson director ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025
Kimberly Jo Tzoumakas director 1170 FAIRFAX STREET, BIRMINGHAM MI 48009